|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||37.13 - 38.62|
|52 Week Range||25.96 - 44.86|
|PE Ratio (TTM)||24.37|
|Earnings Date||Nov 6, 2017 - Nov 10, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||44.83|
GAITHERSBURG, Md., Nov. 20, 2017-- Emergent BioSolutions Inc. today announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for the manufacture ...
GAITHERSBURG, Md., Nov. 14, 2017-- Emergent BioSolutions Inc. announced today that it has issued a Notice of Termination of Conversion Rights for all of its outstanding 2.875% Convertible Senior Notes ...
Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.
Perrigo (PRGO) posts better-than-expected earnings with revenues also beating estimates. The company ups its guidance, courtesy of a continued positive execution across all business segments.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Emergent BioSolutions, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Emergent BioSolutions, Inc. Here are 5 ETFs with the largest exposure to EBS-US. Comparing the performance and risk of Emergent BioSolutions, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Jazz Pharmaceuticals (JAZZ) earnings beat estimates while revenues miss the same in Q3. The company also cuts its guidance due to lower-than-expected sales from Xyrem.
Arena Pharmaceuticals (ARNA) reports another quarter of lackluster Belviq sales. However, the company is likely to advance ralinepag in phase III study based on positive data from the previous stage.
Categories: Yahoo FinanceGet free summary analysis Emergent BioSolutions, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Emergent BioSolutions, Inc. – Merck & Co., Inc., Celgene Corporation, GlaxoSmithKline plc Sponsored ADR and Pfizer Inc. (MRK-US, CELG-US, GSK-US and PFE-US) that have also reported for this ... Read more (Read more...)
The Gaithersburg, Maryland-based company said it had net income of 68 cents per share. Earnings, adjusted for non-recurring costs, came to 73 cents per share. The results exceeded Wall Street expectations. ...
GAITHERSBURG, Md., Nov. 02, 2017-- Emergent BioSolutions Inc. reported financial results for the quarter and nine months ended September 30, 2017.. See“ Reconciliation of Statement of Operations” for a ...
NEW YORK, NY / ACCESSWIRE / November 2, 2017 / Emergent BioSolutions Inc. (NYSE: EBS ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 2, 2017 at 5:00 PM Eastern ...
GAITHERSBURG, Md., Oct. 19, 2017-- Emergent BioSolutions will release its financial results for the third quarter and nine months of 2017 immediately after market close on Thursday, November 2, 2017. The ...
Emergent BioSolutions (EBS) announced that it has acquired FDA-licensed smallpox vaccine's business of Sanofi (SNY) ??? ACAM2000.
GAITHERSBURG, Md., Oct. 06, 2017-- Emergent BioSolutions Inc. announced today that it has completed its acquisition of Sanofi’ s ACAM2000 ®, business, which includes ACAM2000, the only smallpox vaccine ...
Emergent BioSolutions Inc. (EBS) completes the acquisition of anthrax monoclonal antibody, raxibacumab, from GlaxoSmithkline.
GAITHERSBURG, Md., Oct. 04, 2017-- Emergent BioSolutions Inc. today announced that it has been awarded a contract valued at up to approximately $25 million by the U.S. Department of State to supply TROBIGARD™ ...
NEW YORK , Oct. 3, 2017 /PRNewswire/ -- Alere Inc. (ALR) Lifshitz & Miller announces that on August 23, 2017 , the U.S. District Court for the District of Massachusetts denied ALR's motion to dismiss a ...
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Transaction anticipated to be additive by approximately $9 million to revenue and neutral to GAAP net income for full year 2017. GAITHERSBURG, Md., Oct. 03, 2017-- Emergent BioSolutions Inc. announced ...
GAITHERSBURG, Md., Oct. 02, 2017-- Emergent BioSolutions Inc. today announced that it has completed a new five-year, $200 million syndicated senior secured credit facility. This new facility replaces and ...